Covagen AG (acquired by Johnson & Johnson)

Creating the next generation of biologics

Covagen is a privately held company pioneering the commercialization of Fynomers as next generation protein drugs to address unmet medical needs in inflammatory diseases and cancer. Fynomers represent a novel class of protein therapeutics. Due to their favorable biophysical properties, Fynomers with different binding specificities can be combined in a single molecule, thus creating drugs with new mechanisms of action.

Company News

Find here the latest news about the company.

28.06.2022 World shaper of tomorrow: Covagen addresses unmet medical needs with novel protein therapeutics (TOP 100)
17.04.2015 Nine hot start-ups, 400 visitors and Joe Jimenez (startupticker.ch)
25.08.2014 Janssen Affiliate Cilag GmbH International Acquires Covagen AG (startupticker.ch)
05.05.2014 Covagen’s first clinical trials (startupticker.ch)
19.02.2014 Covagen Adds Baxter Ventures as Investor (startupticker.ch)
09.12.2013 Covagen Secures CHF 42 Million in Series B Financing (startupticker.ch)
21.11.2013 Covagen and Tanabe Research Laboratories Expand Strategic Research Collaboration (startupticker.ch)
15.04.2013 Covagen hires experienced Chief Business Officer (startupticker.ch)
18.10.2012 Covagen enters into a partnership and gets EUR 4 million upfront payment (startupticker.ch)
04.01.2012 Important step for Covagen (startupticker.ch)

Creating the next generation of biologics

Company News

Company Awards